Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 350

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

Open access
Kaley, Thomas, Touat, Mehdi, Subbiah, Vivek, Hollebecque, Antoine, Rodon, Jordi, Lockhart, A. Craig, Keedy, Vicki, Bielle, Franck, Hofheinz, Ralf-Dieter, Joly, Florence, Blay, Jean-Yves, Chau, Ian, Puzanov, Igor, Raje, Noopur S., Wolf, Jurgen, DeAngelis, Lisa M., Makrutzki, Martina, Riehl, Todd, Pitcher, Bethany, Baselga, Jose, Hyman, David M.·2018·Journal of Clinical Oncology

Abstract

Purpose: BRAF V600 mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in glioblastoma. We sought to determine the activity of vemurafenib, a selective inhibitor of BRAF V600, in patients with gliomas that harbor this mutation. Patients and Methods: The VE-BASKET study was an open-label, nonrandomized, multicohort study for BRAF V600-mutant nonmelanoma cancers. Patients with BRAF V600-mutant glioma received vemurafenib 960 mg twice per day continuously until disease progression, withdrawal, or intolerable adverse effects. Key end points included confirmed objective response rate by RECIST version 1.1, progression-free survival, overall survival, and safety. Results: Twenty-four patients (median age, 32 years; 18 female and six male patients) with glioma, including malignant diffuse glioma (n = 11; six glioblastoma and five anaplastic astrocytoma), PXA (n = 7), anaplastic ganglioglioma (n = 3), pilocytic astrocytoma (n = 2), and high-grade glioma, not otherwise specified (n = 1), were treated. Confirmed objective response rate was 25% (95% CI, 10% to 47%) and median progression-free survival was 5.5 months (95% CI, 3.7 to 9.6 months). In malignant diffuse glioma, best response included one partial response and five patients with stable disease, two of whom had disease stabilization that lasted more than 1 year. In PXA, best response included one complete response, two partial responses, and three patients with stable disease. Additional partial responses were observed in patients with pilocytic astrocytoma and anaplastic ganglioglioma (one each). The safety profile of vemurafenib was generally consistent with that of previously published studies. Conclusion: Vemurafenib demonstrated evidence of durable antitumor activity in some patients with BRAF V600-mutant gliomas, although efficacy seemed to vary qualitatively by histologic subtype. Additional study is needed to determine the optimal use of vemurafenib in patients with primary brain tumors and to identify the mechanisms driving differential responses across histologic subsets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2018.78.9990

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 350

Metadata

Authors
Kaley, T., Touat, M., Subbiah, V., Hollebecque, A., Rodon, J., Lockhart, A. C., Keedy, V., Bielle, F., Hofheinz, R.-D., Joly, F., Blay, J.-Y., Chau, I., Puzanov, I., Raje, N. S., Wolf, J., DeAngelis, L. M., Makrutzki, M., Riehl, T., Pitcher, B., Baselga, J., & Hyman, D. M.
Venue
Journal of Clinical Oncology
Published
2018-12-10
Volume
36
Issue
35
Pages
3477-3484
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2896001331
Cited by
350
References
7
FWCI
16.32
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study. https://app.cochat.ai/papers/10.1200/jco.2018.78.9990
The paper
Kaley, T., Touat, M., Subbiah, V., Hollebecque, A., Rodon, J., Lockhart, A. C., Keedy, V., Bielle, F., Hofheinz, R.-D., Joly, F., Blay, J.-Y., Chau, I., Puzanov, I., Raje, N. S., Wolf, J., DeAngelis, L. M., Makrutzki, M., Riehl, T., Pitcher, B., . . . Hyman, D. M. (2018). BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2018.78.9990

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.